- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Bioinformatic analysis of SIRT7 sequence and structure. (Pubmed Central) - Sep 24, 2022 Thus, the catalytic domain was found to be quite conserved (83.23% identity) and key residues such as D118, Y119, R120, D170, H187, N189, C198, C225, C228, V273, G298, F239 and V237 were identified...Finally, predicted three-dimensional structures showed a classic structure of the central catalytic region of most sirtuins, while the flanking N- and C-terminal regions were unique to each phylogenetic group. All this helps to understand a little more how SIRT7 works and gives clues for the future design and development of small molecules that benefit human and animal health.Communicated by Ramaswamy H. Sarma.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal: ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer. (Pubmed Central) - Sep 21, 2022 We find that, ARID1A and EGFR-pathway genetic alterations are mutually exclusive across lung and colorectal cancers, further supporting a functional connection between these pathways. Our results not only suggest that ARID1A could be potentially used as a predictive biomarker for cetuximab treatment decisions but also provide a rationale for exploring therapeutic MAPK inhibition in an unexpected but genetically defined segment of CRC patients.
- |||||||||| Ibrance (palbociclib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases: Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma (clinicaltrials.gov) - Sep 21, 2022 P1/2, N=27, Active, not recruiting, Our results not only suggest that ARID1A could be potentially used as a predictive biomarker for cetuximab treatment decisions but also provide a rationale for exploring therapeutic MAPK inhibition in an unexpected but genetically defined segment of CRC patients. Recruiting --> Active, not recruiting | Trial completion date: Dec 2026 --> Dec 2024 | Trial primary completion date: Dec 2024 --> Sep 2022
- |||||||||| MK-1084 / Merck (MSD), Otsuka
Enrollment change, Combination therapy, Monotherapy, Metastases: A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001) (clinicaltrials.gov) - Sep 19, 2022 P1, N=264, Recruiting, ACACB can lead to decreased sensitivity to cetuximab in CRC, and its mechanism may be related to EGFR phosphorylation, which could affect the activation of the mTOR/Akt signaling pathway and regulation of CDT1-, cyclin D1-, and p21-related cell cycle modulation. N=185 --> 264
- |||||||||| Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New trial, Real-world evidence, Real-world, Metastases: A Small-sample, Real-world Study of Sintilimab Plus Bevacizumab/Cetuximab Plus XELOX Regimen for Conversion Therapy in Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Sep 16, 2022 P=N/A, N=10, Recruiting,
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Prevention and management of cetuximab-related hypomagnesemia. (Available On Demand; Poster Bd #: C28) - Sep 15, 2022 - Abstract #ASCOQC2022ASCO_QC_398; Hypomagnesemia is a reversible and manageable cetuximab-related adverse event and should not interfere with treatment outcomes. A periodic check of magnesium levels during treatment with cetuximab is recommended.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Retrospective data, Journal: Informed Bayesian survival analysis. (Pubmed Central) - Sep 14, 2022 The outlined Bayesian framework provides several benefits when applied to parametric survival analyses. It uses data more efficiently, is capable of considerably shortening the length of clinical trials, and provides a richer set of inferences.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Cohort study of subclinical sensitization against galactose-α-1,3-galactose in Japan: Prevalence and regional variations. (Pubmed Central) - Sep 14, 2022 Sensitization to galactose-α-1,3-galactose (α-Gal) leads to the development of α-Gal syndrome, which includes red meat allergy and cetuximab-induced anaphylaxis...The prevalence of subclinical sensitization to α-Gal is estimated at 2.0%-4.0% in Japan and may be higher in rural areas, supporting an association between tick bites and α-Gal sensitization. In contrast, the prevalence of subclinical sensitization to beef is 9.7% in Japan and is highest in Tokyo Metropolis, suggesting the presence of another IgE-binding epitope apart from α-Gal and another sensitization route in the sensitization to beef IgE.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Epigenetic controller: Altered gene expression due to aberrant DNA methylation correlates with responsiveness to anti-EGFR antibody treatment. (Pubmed Central) - Sep 14, 2022 Analysis of the association between cetuximab signature or DNA methylation status and progression-free survival (PFS) of anti-EGFR antibody agents in the same cohort showed that DNA methylation status was most associated with PFS. In conclusion, we found that aberrant DNA methylation regulates specific gene expression in cetuximab signature during carcinogenesis, suggesting that it is one of the important determinants of sensitivity to anti-EGFR antibody agents.
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Supervised Optimal Chemotherapy Regimen Based on Offline Reinforcement Learning. (Pubmed Central) - Sep 14, 2022 The developed model was tested using a manually constructed database of forty Stage-IV colon cancer patients, receiving line-1 chemotherapy treatments, who were clinically classified as 'Bevacizumab based patient' and 'Cetuximab based patient'. Experimental results revealed that the supervision from the oncologists has considered the effect to stabilize chemotherapy regimen and it was suggested that the proposed framework could be successfully used as a supportive model for oncologists in deciding their treatment decisions.
- |||||||||| adagrasib (MRTX849) / Mirati, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical: 🔥 KRYSTAL-1: Update on adagrasib +/- cetuximab in KRASG12C #colorectal cancer 🔥 ✅ 44 pts Ada: ORR 19%, DCR 86%, DOR 4.3, PFS ws 5.6 ✅32 pts ada & cetux; ORR 46%, DCR 100%, DOR 7.6, PFS 6.9, mOS 13.4 💪 new options in mCRC @myESMO @OncoAlert (Twitter) - Sep 12, 2022
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Clinical, Retrospective data, Review, Journal: Post-induction Strategies in Metastatic Colorectal Cancer Patients Treated With First-Line Anti-EGFR-Based Treatment: A Systematic Review and Meta-Analysis. (Pubmed Central) - Sep 10, 2022 The search included RCTs of patients with mCRC treated with an initial period of cytotoxic chemotherapy (CT) in association with anti-EGFR (ie, panitumumab or cetuximab) as first-line regimen, and then switched to one of the following strategies: observation; maintenance with anti-EGFR, fluoropyrimidine (FP), or both; or continuing the induction regimen until disease progression or unacceptable toxicity...In all studies, CT (induction or maintenance with FP) + anti-EGFR until disease progression or unacceptable toxicity prolonged OS (HR = 0.72 [95%CI 0.61-0.86]; P < .01) and PFS (HR = 0.76, 95%CI 0.68-0.85; P < .01) compared to other agents (FP ± bevacizumab) or observation...This effect might be particularly amplified in left-sided BRAF wild-type mCRC patients. A higher level of evidence coming from phase III trials is auspicable.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Biomarker, Journal: Biomarkers of Anti-EGFR Antibodies in the Treatment of Metastatic Colorectal Cancer (Pubmed Central) - Sep 10, 2022 Furthermore, an epigenetic factor, DNA methylation status, was reported to be associated with the therapeutic effect of anti-EGFR treatments, and our subsequent studies have suggested that DNA methylation status is predictive of therapeutic efficacy of anti- EGFR antibodies regardless of the site of the primary tumor. Novel biomarkers will continue to be developed from a variety of approaches to provide more optimal cancer treatment for each individual patient.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Trial completion, Metastases: Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects (clinicaltrials.gov) - Sep 9, 2022 P2, N=43, Completed, Novel biomarkers will continue to be developed from a variety of approaches to provide more optimal cancer treatment for each individual patient. Unknown status --> Completed
- |||||||||| Review, Journal: Radiation therapy and targeted therapies: Risks and opportunities (Pubmed Central) - Sep 7, 2022
Trial completion date: Sep 2022 --> Jul 2023 This review provides a point of view in the current state of knowledge, and its limitations highlight the need for more solid data in a field full of promise.
|